
The use of genetic testing by way of tumor tissue analysis combined with liquid biopsy monitoring at different time points throughout the disease progression of colorectal cancer may help optimize treatment selection.

The use of genetic testing by way of tumor tissue analysis combined with liquid biopsy monitoring at different time points throughout the disease progression of colorectal cancer may help optimize treatment selection.

Targeted Oncology reviews trending news and videos online for the week of March 27, 2020, including recent updates on the impact of COVID-19 in oncology practice and a clinical trial on breast cancer.

An updated analysis from the ALCYONE trial has found that adding daratumumab to a standard-of-care regimen significantly prolonged survival in patients with transplant-ineligible multiple myeloma, according to a recent paper in The Lancet.

In a Targeted Oncology case-based peer perspectives live discussion, Heather A. Wakelee, MD, discussed treatment with tyrosine kinase inhibitor treatment options for a real-world Hispanic patient with EGFR-mutant non–small cell lung cancer.<br />

Melphalan flufenamide in combination with dexamethasone achieved an overall response rate of 26% in patients with relapsed/refractory multiple myeloma, according to results from the pivotal phase II HORIZON study. The achievement serves as basis for the submission of a New Drug Application to the FDA.

In an interview with Targeted Oncology, James L. Ferrara, MD, discussed the prognosis of patients with graft-versus-host-disease and the current treatment strategies. He also highlighted his experience with ruxolitinib and the remaining challenges in this space.

Treatment with an investigational targeted anti-cancer gene-therapy agent, VB-111, in addition to paclitaxel met the pre-specified efficacy criterion of an absolute percentage advantage of 10% or higher CA-125 response rate in patients with platinum-resistant ovarian cancer, according to results from the planned interim analysis of the phase III OVAL trial.<br />

In an interview with Targeted Oncology, Gurbakhah Kaur, MD, discussed the evolution of the multiple myeloma treatment landscape. She also highlighted other agents that are being evaluated in this patient population, both with BCMA targets and different targets.

The spread of COVID-19 has slowed down processes in many areas of health care, and there is widespread curiosity on how the pandemic will impact regulatory action in the United States. In the oncology community, providers and their patients await vital drugs that have been shown to approve upon survival and in some case are considered curative for different cancers.

In an interview with Targeted Oncology, Timothy D. Moore, MD, discussed how his institution is handling concerns regarding coronavirus disease 2019 and what he is seeing with patients and cancer programs.

Patients with early-stage breast cancer who received pelareorep demonstrated consistent data with safety run-in data and had a favorable toxicity profile, according to an cohort analysis from the window-of-opportunity study, AWARE-1.

In an interview with Targeted Oncology, Patrick Brown, MD, discussed the results from the randomized phase III study evaluating blinatumomab in patients with B-acute lymphoblastic leukemia.

The addition of cetuximab to irinotecan, fluorouracil, and folinic acid leucovorin demonstrated superior overall survival compared with the addition of bevacizumab in patients with metastatic colorectal cancer who developed skin toxicity from cetuximab exposure, according to results from the phase II FIRE-3 trial, published in the Annals of Oncology.

The FDA has granted a fast track designation a combination of novel selective PI3K-gamma inhibitor IPI-549 plus nivolumab for the treatment of patients with advanced urothelial cancer, according to a press release from developer Infinity Pharmaceuticals.

Due to the coronavirus disease 2019 concerns, the American Society of Clinical Oncology Board has made the decision to deliver the latest science virtually during the timeframe of the scheduled Annual Meeting, which would have been held in Chicago, IL, May 29 to June 2, 2020.

In an interview with Targeted Oncology, Tania Jain, <a>MBBS,</a> discussed the role of transplant as treatment of patients with myelofibrosis and the challenges that remain in this space. She also spoke to the treatment options for patients with graft-versus-host-disease.

The mortality rate for cutaneous melanoma was significantly reduced between 2013 to 2016 as a result of new targeted therapies for metastatic disease, according to a recent report in the American Journal of Public Health. It is the largest death decline ever recorded for skin cancer.

Despite demonstrating improvement in overall survival as treatment of patients with advanced inoperable metastatic colorectal cancer, cetuximab plus chemotherapy led to significantly worse survival for patients with operable colorectal liver metastases in the perioperative setting, according to findings from randomized phase III clinical trial.

The FDA has approved a new 420-mg multi-dose vial of Ontruzant a biosimilar of trastuzumab, according to a press release from Samsung Bioepis.

In an open letter to the President of the United States, the Community Oncology Alliance brings attention to the critical needs of patients with cancer. Community Oncology Alliance requests all private health insurance companies immediately waive all “prior authorization” requirements for cancer treatments, which pose threat to cancer treatment, particularly in patients who are elderly and among the most vulnerable in the United States to contract COVID-19.

A significant percentage of younger men with high-risk prostate cancer who display minimal comorbidities continue to receive nondefinitive therapy (NDT), despite research that has demonstrated local therapy is more beneficial in this patient population, according to findings from a study published in <em>JAMA Oncology</em> show. A number of reasons for this have been identified, including insurance status and race/ethnicity.

In an interview with Targeted Oncology, Kashyap Patel, MD, discussed the COVID-19 pandemic and the implementation of new precautions in his practice as the number of COVID-19 infected persons rises in the state.<br />

Oncologists have unanswered questions about how to deal with resistance mechanisms for multikinase inhibitors and selective RET inhibitors, and how efficacy is impacted when they combine 2 or more such drugs into a treatment regimen for RET-positive lung cancer. In a paper, researchers led by Vivek Subbiah, et al review the existing data.

Venetoclax in combination with azacytidine demonstrated a statistically significant improvement in overall survival and achieved a satisfactory composite complete remission rate in previously untreated patients with acute myeloid leukemia, meeting the co-primary end points of the phase III VIALE-A study. Genentech, the developer of venetoclax, announced the positive news in a press release, also noting that safety profiles of both drugs were consistent with prior reports.

The addition of 6 months of oral daily enzalutamide to standard salvage radiation and hormone therapy is safe and may improve prostate cancer remission rates at 2 and 3 years postoperatively among patients with high-risk disease, according to a recent paper in European Urology Oncology.

In an interview with Targeted Oncology, Massimo Lazzari, MD, discussed the findings from the analysis of microbiota in patients with bladder cancer. He highlighted how these findings can impact the treatment paradigm and exploration of new therapeutic agents in this space.

Oncology Venture has met with the FDA to discuss a potential path forward for the approval of dovitinib as a treatment for patients with renal cell carcinoma, according to a press release from the company.

In an interview with Targeted Oncology, Randall A. Oyer, MD, discussed how his institution is handling the pandemic while still accommodating patients who are already on clinical trials and making sure everyone stays safe.

Treatment with pembrolizumab demonstrated antitumor activity along with tolerable toxicity in patients with 4 different rare and hard-to-treat malignancies, according to results from a phase II study led by The University of Texas MD Anderson Cancer Center researchers and published in the Journal for ImmunoTherapy of Cancer.

As the COVID-19 pandemic evolves, healthcare providers in the oncology realm are faced with a number of unforeseen challenges requiring immediate attention and swift changes in policies. Experts at the Seattle Cancer Care Alliance shared their insights and advice with the public in a recent article to demonstrate how they have adapted to provide the most optimal care for patients with cancer in light of the COVID-19 outbreak.